FileToto: The Bristol Myers Squibb Research and Development Center in Cambridge Crossing in Cambridge, Massachusetts, on December 27, 2023.
Adam Glanzman | Bloomberg | Getty pictures
Bristol Myers Squibb On Thursday, estimates defeated in the first quarter and increased his sales and profit guidelines for the year because the drug manufacturer lowers the costs.
The company now expects that 2025 revenue between $ 45.8 billion and $ 46.8 billion will be increased, which increases an earlier outlook of around $ 45.5 billion. Bristol Myers also expects adjusted profit of $ 6.70 to 70 per share, which is compared with its previous forecast from USD 6.85 per share.
Remarkably, the company indicated that its guidelines include the estimated effects of current tariffs on US products that were delivered to China. However, they do not explain any of President Donald Trump's planned tariffs imported in the USA, said Bristol Myers.
China is a critical market for Bristol Myers Squibb. The company previously described its “China 2030 strategy”, which is a plan to bring more medication into the nation in order to satisfy the non -fulfilled medical needs in areas such as stomach cancer and to include more Chinese patients in clinical studies.
The company said that the increase in views reflects the strength of the company of the newer drug brands and the expected sales in the first quarter from its legacy portfolio of older medication.
The results come when Bristol Myers Squibb lowers at the end of 2027 at the expense of 2 billion US dollars, which corresponds to $ 1.5 billion by the end of this year.
It is only a few days after Bristol Myers Squibbs recently approved Schizophrenia medicines, Cobenfy, disappointed in a large clinical study that caused some Wall Street analysts to significantly reduce their sales forecasts for treatment with several billion dollars.
The company is committed to Cobenfy and other so-called growth portfolio medication in order to compensate for the loss of sales through the best-selling treatments that are supposed to lose exclusivity on the market, including the blockbuster blood thinner Eliquis and the OPDIVO cancer.
Here is what Bristol Myers reported in the first quarter compared to what Wall Street expected, based on a survey of LSEG analysts:
- Win each share: $ 1.80 adapted compared to USD 1.49
- Revenue: 11.2 billion US dollars expected compared to $ 10.7 billion
Bristol Myers achieved a net profit of 2.5 billion US dollars or $ 1.20 per share in the first quarter. This is compared to a net loss of $ 11.9 billion or a loss of $ 5.89 per share for the period of previous year.
Without certain items, it reported an adjusted result per share of USD 1.80 for the quarter.
The sales of the pharmaceutically fell 6% to 11.2 billion US dollars compared to the same period in the previous year.
Eliquis booked the sales of $ 3.57 billion for the quarter, which decreased by 4% last year. This is above the analysts of 3.34 billion US dollars expected by the analysts, as created by StreetCcount.
The blood thinner, which Bristol Myers shares with Pfizer, will probably lose market excessiveness by 2028.
The sale of Eliquis could also score in 2026 if a new negotiated price for the drug for certain Medicare patients comes into force after negotiations with the Federal Government. These price talks are an important determination of the inflation reduction law.
The second round of negotiations aims at 15 additional medication and sets new prices that come into force in 2028. This includes the Bristol Myers medication Pomalyyst, which is used to treat blood cancer, which is called multiple myeloma, and another cancer that develops in people with HIV.
The pomalyyst earned $ 658 million for the period, which decreased 24% compared to the same period in the previous year. Revlimid, a medication for the treatment of adults with a multiple myeloma, decreased in sales of 936 million US dollars in the first quarter, which decreased by 44% compared to the same period last year.
Sales from the company's so-called growth portfolio was $ 5.56 billion in the first quarter, which increased an increase of 16% compared to the same period in the previous year.
OPDIVO generated sales of $ 2.27 billion in the first quarter and rose by 9% compared to the same period last year. This is above the estimation of the analysts of 2.16 billion US dollars for the quarter, said StreetCcount.
In the meantime, Cobenfy booked 27 million US dollars for the first quarter.
Comments are closed.